What is Lifesci Capital’s Forecast for Surrozen Q1 Earnings?

Surrozen, Inc. (NASDAQ:SRZN) – Research analysts at Lifesci Capital decreased their Q1 2026 EPS estimates for shares of Surrozen in a research note issued on Monday, March 23rd. Lifesci Capital analyst P. Dolezal now expects that the company will post earnings per share of ($2.06) for the quarter, down from their previous forecast of ($1.82). The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. Lifesci Capital also issued estimates for Surrozen’s Q2 2026 earnings at ($2.10) EPS, Q3 2026 earnings at ($2.17) EPS, Q4 2026 earnings at ($1.23) EPS and FY2026 earnings at ($4.73) EPS.

Surrozen (NASDAQ:SRZN) last released its earnings results on Monday, March 23rd. The company reported ($7.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.29) by ($6.30). The company had revenue of $0.53 million for the quarter, compared to analyst estimates of $0.66 million. Surrozen had a negative net margin of 7,476.67% and a negative return on equity of 1,240.42%.

SRZN has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and set a $36.00 price objective (up from $32.00) on shares of Surrozen in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and issued a $40.00 target price on shares of Surrozen in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised Surrozen to a “sell” rating in a research note on Friday, November 28th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Surrozen has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Surrozen Trading Up 7.1%

NASDAQ:SRZN opened at $28.00 on Thursday. The stock has a market capitalization of $239.96 million, a price-to-earnings ratio of -0.84 and a beta of 0.53. The firm has a fifty day simple moving average of $24.50 and a two-hundred day simple moving average of $18.87. Surrozen has a 12 month low of $5.90 and a 12 month high of $29.59.

Hedge Funds Weigh In On Surrozen

A number of hedge funds have recently added to or reduced their stakes in SRZN. Braidwell LP purchased a new stake in shares of Surrozen in the second quarter worth approximately $1,252,000. Stempoint Capital LP lifted its holdings in shares of Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after purchasing an additional 445,713 shares in the last quarter. Stonepine Capital Management LLC boosted its position in shares of Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after buying an additional 20,247 shares during the last quarter. Boothbay Fund Management LLC purchased a new position in shares of Surrozen during the fourth quarter valued at approximately $414,000. Finally, Quadrature Capital Ltd bought a new stake in Surrozen during the fourth quarter worth $335,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Insiders Place Their Bets

In other Surrozen news, Director Tim Kutzkey bought 18,052 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was bought at an average cost of $19.60 per share, with a total value of $353,819.20. Following the completion of the transaction, the director directly owned 1,016,658 shares in the company, valued at approximately $19,926,496.80. The trade was a 1.81% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Group Gp Lp Column III bought 18,052 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The shares were acquired at an average cost of $19.60 per share, with a total value of $353,819.20. Following the completion of the transaction, the insider owned 1,016,658 shares of the company’s stock, valued at $19,926,496.80. This represents a 1.81% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have acquired 330,291 shares of company stock worth $7,478,785. Insiders own 45.18% of the company’s stock.

Trending Headlines about Surrozen

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Large insider buys by major shareholder TCG Crossover GP II — the fund bought 106,658 shares on March 24 (~$24.69 avg) and has repeatedly purchased stock in March, signaling strong insider conviction that can support the share price. SEC Filing
• Positive Sentiment: Additional TCG purchase: 15,223 shares on March 23 (~$24.90 avg), a follow-on buy that reinforces the insider buying narrative. InsiderTrades article
• Positive Sentiment: HC Wainwright reiterated a “Buy”, raised multi-quarter and multi-year EPS projections (less negative) and set a $36 price target — a constructive analyst view that can attract demand. Article
• Positive Sentiment: Cantor Fitzgerald assigned an “Overweight” rating with a higher price target (reported this week), providing another institutional buy-side signal. Article
• Neutral Sentiment: Institutional ownership is high (many hedge funds hold SRZN) and several institutions increased positions in recent quarters — supportive for liquidity but not an immediate catalyst.
• Negative Sentiment: Lifesci Capital cut multiple near-term EPS estimates (Q1–Q4 2026 and FY2026), making its outlook more pessimistic and creating downside pressure for sentiment. MarketBeat coverage
• Negative Sentiment: Recent quarterly results (reported March 23) were a significant miss (EPS deeply negative vs. expectations) and the company remains loss-making with volatile margins — a fundamental risk that keeps shares speculative despite positive headlines. Earnings detail

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.